BeiHai Bio Secures Nearly RMB 200 Million in Series B Funding to Advance Differentiated Oncology Pipeline

Recently,Beihai Biotech(hereinafter referred to as “Beihai Biotech”) announced the completion of its Series B financing round, raising nearly RMB 200 million. This round of financing was led byYikai Venture CapitalLead Investor, Existing ShareholdersGuozhong CapitalContinue to increase investment,Yuanhe ChenkunJingu Capital、Qingdao Hongteng、Jinhang InvestmentPending co-investment by investors. The funds from this round of financing will be used forClinical Development of the Company’s Core Products，Submission of Marketing Application for First Blockbuster Candidate BH009andTeam Expansionand other aspects.

Beihai Biotech is a biopharmaceutical company developing differentiated innovative oncology products, dedicated to creating patient-centric innovative cancer therapies that address unmet clinical needs.The Company has established a pipeline of more than 10 innovative drug candidates through multiple first-in-class new drug technology platforms, with several new drug projects having advanced to the New Drug Application (NDA) filing and pivotal clinical trial stages. It has cumulatively obtained in China and the United States7 Investigational New Drug (IND) Applications。

BH009is independently developed by Beihai Biotech with significant clinical advantagesInnovative Docetaxel Product。Currently, there are no similar products available on the global market.Docetaxel is one of the cornerstone drugs used in first-line oncology treatment and is widely employed in the management of solid tumors. This isCurrently the world's firstDocetaxel Innovative Product Successfully Meets Clinical Endpoints in Pivotal Trials, Poised to Become the First Approved Docetaxel Innovative Product in Both the Chinese and U.S. Markets

Dr. Sun Qun, Founder and Chairman of Beihai BiotechIndicates:

“We sincerely appreciate the investors’ recognition and support for Beihai Biotech. This round of financing marks another milestone in Beihai Biotech’s rapid development. The successful completion of the Series B financing not only reflects the investors’ acknowledgment of the Beihai team’s innovation and industrialization capabilities, but also demonstrates their strong confidence in the highly differentiated product pipeline that Beihai has established in the field of innovative oncology drugs, as well as in the commercial prospects of its future products. Beihai aims to become an internationally leading innovative pharmaceutical company, capable of developing and successfully launching blockbuster innovative products with billion-dollar potential. We will further strengthen our efforts in technological innovation and talent acquisition, accelerate the development of our product pipeline, and strive to provide safer and more effective new treatment options for cancer patients.”

Fang Kai, Chairman of Yikai Venture CapitalMr. stated:

Beihai Biotech is an innovative drug R&D enterprise that is professional, focused, efficient, and progressive, leveraging proprietary platform technologies. Its founding team boasts robust R&D capabilities and possesses profound insights into industry dynamics and clinical needs. We are delighted to partner with Beihai Biotech, a team characterized by sustained creativity and high-efficiency execution, supporting the company’s continuous innovation and advancement in drug delivery technologies and PDC (Peptide-Drug Conjugate) therapeutics. We look forward to and are confident that Beihai Biotech will emerge as an international, high-value innovative oncology pharmaceutical company.

Qingdao Yikai Venture Capital Management Co., Ltd. was established in November 2020. Its core team members are all graduates of prestigious universities such as Peking University and Fudan University, and possess over ten years of continuous experience in equity investment management and professional expertise within the investment industry. Their prior investment experience spans the energy sector as well as the medical and pharmaceutical sectors. In the pharmaceutical field, this includes establishing funds respectively with government platforms of Licheng District in Jinan City and Laoshan District in Qingdao City, to invest in leading medical device companies and innovative drug R&D enterprises. The company has completed investments totaling more than RMB 400 million in the healthcare industry. Portfolio companies include eTheRNA, a global leader in mRNA technology based in Belgium; Beijing New羿 Biotechnology (Xinyi Biotech), a leading Chinese digital PCR enterprise; and Shanghai Jiangeng Medical, a global pioneer in organ transplantation perfusion equipment and solutions.

Guozhong Capital currently manages two physical funds under the National SME Development Fund, with total assets under management reaching RMB 10 billion. Guozhong Capital focuses on high-quality enterprises in sectors such as big data, cloud computing, cybersecurity, and enterprise services; semiconductors, electronic information technology, and artificial intelligence; new consumption and internet applications; new energy vehicles and intelligent driving; new materials, new energy, ecological protection, and intelligent equipment; as well as biopharmaceuticals and general health. Since commencing formal operations over six years ago, Guozhong Capital has seen 22 of its portfolio companies go public, and 12 achieve exit through mergers and acquisitions by listed companies. Representative cases include Empyrean Technology, Oriental Semiconductor, Mindray Medical, Jiayuan Technology, Bangyan Technology, Zelt Pharma, RemeGen, Hymson, Shijia Photons, and Transwarp.

Jingu Capital is a private equity direct investment platform established by Yuanhe Chenkun in 2021. Leveraging Yuanhe Chenkun’s robust industrial community, comprehensive operational system, extensive industry coverage, and high-quality project resources, Jingu Capital focuses on investing in growth-stage companies with long-term value in three key sectors: technology, biomedicine, and consumption upgrading. The Jingu Capital direct investment fund and the Yuanhe Chenkun fund of funds operate as an integrated entity with seamless collaboration, while maintaining independent, market-oriented operational mechanisms. Since its inception, the platform’s unique advantages and positioning have garnered widespread attention from the industry and high recognition from portfolio companies.

Zhuhai Jinhang Industrial Investment Group Co., Ltd. is a wholly state-owned enterprise under the jurisdiction of Jinwan District, Zhuhai City. Established on February 5, 2016, with a registered capital of RMB 1.207 billion, the company currently has total assets of approximately RMB 4 billion. Focusing on strategic emerging industries, it invests in enterprises in fields such as biopharmaceuticals and electronic information through funds and direct investments.